Draft guidance in the form of additional Q&As on biosimilar applications and issues around interchangeability has been opened for comment until 19 January 2021 by the US Food and Drug Administration. The document provides questions and answers that build on existing Q&A guidelines on the topic.
On the question of how applicants should seek FDA review for biosimilars that they wish to be deemed interchangeable, the...






